Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors and a team of industry […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!